The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis
Open accessAbstract
BACKGROUND: Hyperactivity of the IL-23/IL-17 axis is central to plaque psoriasis pathogenesis. Secukinumab, a fully human mAb that selectively inhibits IL-17A, is approved for treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab improves the complete spectrum of psoriasis manifestations, with durable clinical responses beyond 5 years of treatment. In the feed-forward model of plaque chronicity, IL-17A has been hypothesized as the key driver of pathogenic gene expression by lesional keratinocytes, but in vivo evidence in human subjects is lacking. METHODS: We performed a randomized, double-blind, placebo-controlled study (NCT01537432) of patients receiving secukinumab at the clinically approved dose up to 12 weeks. We then correlated plaque and nonlesional skin transcriptomic profiles with histopathologic and clinical measures of efficacy. RESULTS: After 12 weeks of treatment, secukinumab reversed plaque histopathology in the majority of patients and modulated thousands of transcripts. Suppression of the IL-23/IL-17 axis by secukinumab was evident at week 1 and continued through week 12, including reductions in levels of the upstream cytokine IL-23, the drug target IL-17A, and downstream targets, including β-defensin 2. Suppression of the IL-23/IL-17 axis by secukinumab at week 4 was associated with clinical and histologic responses at week 12. Secukinumab did not affect ex vivo T-cell activation, which is consistent with its favorable long-term safety profile. CONCLUSION: Our data suggest that IL-17A is the critical node within the multidimensional pathogenic immune circuits that maintain psoriasis plaques and that early reduction of IL-17A-dependent feed-forward transcripts synthesized by hyperplastic keratinocytes favors plaque resolution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997 · cited 3×
“org).(25) Because efalizumab, a psoriasis therapy that reduces T-cell activation, was withdrawn from themarket in 2009 because of serious infections such as progressivemultifocal leukoencephalopathy,(32) we tested whether secukinumab affected T-cell activation.”
BackgroundResultInfluentialInhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis
Bachelez, H., Choon, S.-E., Marrakchi, S., Burden, A. D., Tsai, T.-F., Morita, A., Turki, H., Hall, D. B., Shear, M., Baum, P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1811317 · Cited by 292 · cited 1×
“Of note, inhibition of the IL-36 pathway was recently shown to be efficacious in patients with pustular psoriasis.(54) IL19 also showed early downregulation by secukinumab in responders, just missing significance (q 5 0.”
Amatya, N., Childs, E. E., Cruz, J. A., Aggor, F. E. Y., Garg, A. V., Berman, A. J., Gudjonsson, J. E., Atasoy, U., & Gaffen, S. L. (2018) · Science Signaling · doi:10.1126/scisignal.aat4617 · Cited by 75 · cited 1×
“In it, TH17-derived IL-17A and IL17F induce massive overproduction of inflammatory products, such as IL-17C, IL-36, IL-19, CCL20, CXCL chemokines, and S100 proteins, in psoriatic KCs, in turn altering resident skin cell homeostasis and further attracting activated leukocyte subsets to maintain plaques.(7,16,17) KC-pro…”
BackgroundSwindell, W. R., Xing, X., Voorhees, J. J., Elder, J. T., Johnston, A., & Gudjonsson, J. E. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00022.2014 · Cited by 42
Cited by
Pathogenesis and virulence of Candida albicans
Lopes, J. P., & Lionakis, M. S. (2022) · Virulence · doi:10.1080/21505594.2021.2019950 · Cited by 477
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Furue, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155382 · Cited by 419
Interleukin-17A and Keratinocytes in Psoriasis
Furue, M., Furue, K., Tsuji, G., & Nakahara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041275 · Cited by 300
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312793 · Cited by 192
Metadata
- Authors
- Krueger, J. G., Wharton, K. A., Schlitt, T., Suprun, M., Torene, R. I., Jiang, X., Wang, C. Q., Fuentes-Duculan, J., Hartmann, N., Peters, T., Koroleva, I., Hillenbrand, R., Letzkus, M., Yu, X., Li, Y., Glueck, A., Hasselberg, A., Flannery, B., Suárez-Fariñas, M., & Hueber, W.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 144
- Issue
- 3
- Pages
- 750-763
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2946192037
- Cited by
- 188
- References
- 5
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. https://app.cochat.ai/papers/10.1016/j.jaci.2019.04.029
- The paper
- Krueger, J. G., Wharton, K. A., Schlitt, T., Suprun, M., Torene, R. I., Jiang, X., Wang, C. Q., Fuentes-Duculan, J., Hartmann, N., Peters, T., Koroleva, I., Hillenbrand, R., Letzkus, M., Yu, X., Li, Y., Glueck, A., Hasselberg, A., Flannery, B., Suárez-Fariñas, M., & Hueber, W. (2019). IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2019.04.029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.